• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验适应性富集设计中数据驱动亚组的治疗评估

Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.

作者信息

Zhang Zhiwei, Chen Ruizhe, Soon Guoxing, Zhang Hui

机构信息

Department of Statistics, University of California at Riverside, Riverside, California, USA.

Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois, USA.

出版信息

Stat Med. 2018 Jan 15;37(1):1-11. doi: 10.1002/sim.7497. Epub 2017 Sep 26.

DOI:10.1002/sim.7497
PMID:28948633
Abstract

Adaptive enrichment designs (AEDs) of clinical trials allow investigators to restrict enrollment to a promising subgroup based on an interim analysis. Most of the existing AEDs deal with a small number of predefined subgroups, which are often unknown at the design stage. The newly developed Simon design offers a great deal of flexibility in subgroup selection (without requiring pre-defined subgroups) but does not provide a procedure for estimating and testing treatment efficacy for the selected subgroup. This article proposes a 2-stage AED which does not require predefined subgroups but requires a prespecified algorithm for choosing a subgroup on the basis of baseline covariate information. Having a prespecified algorithm for subgroup selection makes it possible to use cross-validation and bootstrap methods to correct for the resubstitution bias in estimating treatment efficacy for the selected subgroup. The methods are evaluated and compared in a simulation study mimicking actual clinical trials of human immunodeficiency virus infection.

摘要

临床试验的适应性富集设计(AEDs)允许研究者根据中期分析将入组限制在一个有前景的亚组。现有的大多数AEDs处理少量预先定义的亚组,而这些亚组在设计阶段通常是未知的。新开发的西蒙设计在亚组选择方面提供了很大的灵活性(无需预先定义亚组),但没有提供估计和检验所选亚组治疗效果的程序。本文提出了一种两阶段AED,它不需要预先定义亚组,但需要一个基于基线协变量信息选择亚组的预先指定算法。有一个预先指定的亚组选择算法使得使用交叉验证和自助法来校正估计所选亚组治疗效果时的重代入偏差成为可能。在一项模拟人类免疫缺陷病毒感染实际临床试验的模拟研究中对这些方法进行了评估和比较。

相似文献

1
Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.临床试验适应性富集设计中数据驱动亚组的治疗评估
Stat Med. 2018 Jan 15;37(1):1-11. doi: 10.1002/sim.7497. Epub 2017 Sep 26.
2
Interim treatment selection with a flexible selection margin in clinical trials.临床试验中具有灵活选择边界的中间治疗选择。
Stat Med. 2013 Jul 10;32(15):2529-43. doi: 10.1002/sim.5693. Epub 2012 Dec 5.
3
Point estimation in adaptive enrichment designs.适应性富集设计中的点估计
Stat Med. 2017 Nov 10;36(25):3935-3947. doi: 10.1002/sim.7412. Epub 2017 Aug 7.
4
Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.基于生物标志物的人群富集,用于具有事件发生时间终点的适应性肿瘤学试验。
Stat Med. 2014 Nov 20;33(26):4515-31. doi: 10.1002/sim.6272. Epub 2014 Jul 30.
5
Subgroup analysis with semiparametric models toward precision medicine.亚组分析与精准医学的半参数模型。
Stat Med. 2018 May 20;37(11):1830-1845. doi: 10.1002/sim.7638. Epub 2018 Mar 25.
6
Timing of the interim analysis in adaptive enrichment designs.适应性富集设计中的期中分析时机。
J Biopharm Stat. 2018;28(4):622-632. doi: 10.1080/10543406.2017.1372769. Epub 2017 Oct 30.
7
Biomarker threshold adaptive designs for survival endpoints.用于生存终点的生物标志物阈值适应性设计。
J Biopharm Stat. 2018;28(6):1038-1054. doi: 10.1080/10543406.2018.1434191. Epub 2018 Feb 13.
8
Response adaptive designs with a variance-penalized criterion.具有方差惩罚准则的响应自适应设计。
Biom J. 2009 Oct;51(5):763-73. doi: 10.1002/bimj.200800233.
9
Response-adaptive designs for continuous treatment responses in phase III clinical trials: A review.III期临床试验中连续治疗反应的适应性设计综述
Stat Methods Med Res. 2016 Feb;25(1):81-100. doi: 10.1177/0962280212441424. Epub 2012 Mar 16.
10
Population enrichment designs: case study of a large multinational trial.人群富集设计:一项大型跨国试验的案例研究
J Biopharm Stat. 2011 Jul;21(4):831-45. doi: 10.1080/10543406.2011.554129.

引用本文的文献

1
Latest Developments in "Adaptive Enrichment" Clinical Trial Designs in Oncology.肿瘤学中“适应性富集”临床试验设计的最新进展。
Ther Innov Regul Sci. 2024 Nov;58(6):1201-1213. doi: 10.1007/s43441-024-00698-3. Epub 2024 Sep 13.
2
Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies.迈向重症监护研究的精准化:观察性和干预性研究方法。
Crit Care Med. 2024 Sep 1;52(9):1439-1450. doi: 10.1097/CCM.0000000000006371. Epub 2024 Aug 15.
3
IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
IBIS:采用贝叶斯富集设计识别基于生物标志物的亚组,以进行靶向联合治疗。
BMC Med Res Methodol. 2023 Mar 20;23(1):66. doi: 10.1186/s12874-023-01877-w.
4
A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.两阶段自适应临床试验设计,在中期分析时采用数据驱动的亚组识别。
Pharm Stat. 2022 Sep;21(5):1090-1108. doi: 10.1002/pst.2208. Epub 2022 Mar 24.
5
Multi-stage adaptive enrichment trial design with subgroup estimation.多阶段自适应富集试验设计与亚组估计。
J Biopharm Stat. 2020 Nov 1;30(6):1038-1049. doi: 10.1080/10543406.2020.1832109. Epub 2020 Oct 18.
6
Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.贝叶斯亚组分析方法及相关适应性临床试验设计
JCO Precis Oncol. 2019 Oct 24;3. doi: 10.1200/PO.19.00003. eCollection 2019.
7
Auxiliary variable-enriched biomarker-stratified design.辅助变量富集生物标志物分层设计。
Stat Med. 2018 Dec 30;37(30):4610-4635. doi: 10.1002/sim.7938. Epub 2018 Sep 16.